{"id":"nct:NCT06494501","kind":"trial","title":"The Prevent Coronary Artery Disease Trial","authors":["Icahn School of Medicine at Mount Sinai"],"author_count":1,"year":2024,"published":"2024-07-10","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06494501","source_url":"https://clinicaltrials.gov/study/NCT06494501","archive_url":"https://space-kitty.com/papers/nct:NCT06494501","updated":"2025-04-29","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"Despite increasing evidence that exposure to cardiovascular risk factors (CVRF) at an early age increases the prevalence of subclinical atherosclerosis and is associated with a greater risk of cardiovascular events later in life, there is a lack of randomized trial evidence to support primary prevention strategies in adults aged 30-50 years. The researchers have designed a randomized controlled trial to evaluate whether strict control of CVRF in young adults without known cardiovascular disease, will reduce the progression of total atherosclerosis burden, a surrogate endpoint for symptomatic cardiovascular disease, compared with usual care. The researchers propose a randomized controlled trial enrolling 1,600 healthy young adults who meet the inclusion criteria and who do not meet any exclusion criteria. Eligible study participants will be randomized, in a 1:1 ratio, to either the intervention group (active treatment strategy) or to the control group (guideline-directed medical therapy). Randomization will be stratified by the presence or absence of atherosclerotic plaque in vascular ultrasound.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Atherosclerotic Cardiovascular Disease"],"details":{"acronym":"PRECAD","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1600,"sponsor":"Icahn School of Medicine at Mount Sinai","conditions":["Atherosclerotic Cardiovascular Disease"],"interventions":["DRUG: Inclisiran"],"start_date":"2024-09-12","start_date_type":"ACTUAL","primary_completion_date":"2032-06-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}